ProCE Banner Activity

Mosunetuzumab, a CD20 x CD3 Bispecific Antibody, in R/R Follicular Lymphoma With ≥2 Previous Therapies: Pivotal Phase II Trial Results

Slideset Download
Conference Coverage
Results from the pivotal phase II trial of mosunetuzumab showed significantly higher CR rates vs historical control in patients with relapsed/refractory FL and ≥2 previous lines of therapy.

Released: December 22, 2021

Expiration: December 21, 2022

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation